SELNET clinical practice guidelines for bone sarcoma

Bone sarcoma are infrequent diseases, representing < 0.2% of all adult neoplasms. A multidisciplinary management within reference centers for sarcoma, with discussion of the diagnostic and therapeutic strategies within an expert multidisciplinary tumour board, is essential for these patients, given its heterogeneity and low frequency. This approach leads to an improvement in patient's outcome, as demonstrated in several studies. The Sarcoma European Latin-American Network (SELNET), aims to improve clinical outcome in sarcoma care, with a special focus in Latin-American countries. These Clinical Practice Guidelines (CPG) have been developed and agreed by a multidisciplinary expert group (including medical and radiation oncologist, surgical oncologist, orthopaedic surgeons, radiologist, pathologist, molecular biologist and representatives of patients advocacy groups) of the SELNET consortium, and are conceived to provide the standard approach to diagnosis, treatment and follow-up of bone sarcoma patients in the Latin-American context

Sinovitis villonodular de la articulación coxofemoral, presentación atípica: reporte de caso y revisión de la literatura

ResumenIntroducciónLa sinovitis villonodular pigmentada (SNVP) es una entidad clínica poco frecuente, con una incidencia mayor en las mujeres 3:1, y una edad de presentación entre los 20-40 años de edad. La cadera es un sitio poco común de presentación, estando involucrada en tan solo el 15% de todos los casos.Reporte de casoVarón de 47 años con cuadro de 10 años de evolución, caracterizado por limitación de arcos de movilidad, dolor asociado a aumento de volumen y acortamiento de miembro pélvico, estudios de imagen con destrucción de articulación coxofemoral y extensión a pelvis, reporte histopatológico de SNVP, manejado con hemipelvectomía externa izquierda.ConclusionesLa presentación de la SNVP difusa en la cadera tiene una incidencia baja y un comportamiento localmente agresivo, es necesario tener en cuenta diagnósticos diferenciales que incluyan neoplasias malignas, el estándar de tratamiento es quirúrgico.AbstractIntroductionPigmented villonodular synovitis is an uncommon clinical condition, with a higher incidence in women of 3:1, and an age of presentation between 20-40 years old. The hip is an uncommon site, being involved in only 15% of all cases.Case reportA 47 year-old male 47 years with a history of 10 years onset, characterised by limited range of movement, pain associated with increased volume and shortening of pelvic limb. Imaging studies showed destruction of hip joint and extension to the pelvis. The histopathology reported pigmented villonodular synovitis. Treatment included a left outer hemipelvectomy.ConclusionsThe presentation of a diffuse pigmented villonodular synovitis hip has a low incidence and its locally aggressive behaviour makes it necessary to perform differential diagnoses to include malignancies. The standard treatment is surgical

Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer

Abstract Background Ovarian cancer (OC) is considered the most lethal gynecological cancer, of which more than 65% cases are diagnosed in advanced stages, requiring platinum-based neoadjuvant chemotherapy (NACT). Methods A prospective-longitudinal study was conducted among women with advanced epithelial ovarian cancer (AEOC), III and IV stages, and treated with NACT, at the National Cancer Institute – Mexico, from July 2017 to July 2018. Serum samples were obtained for quantification of CA125 and HE4 using ELISA at the first and in each of the three NACT cycles. The therapeutic response was evaluated through standard tomography. We determined whether CA125 and HE4, alone or in combination, were associated with TR to NACT during follow up. Results 53 patients aged 38 to 79 years were included, 92.4% presented papillary serous subtype OC. Higher serum HE4 levels were observed in patients with non-tomographic response (6.89 vs 5.19 pmol/mL; p = 0.031), specially during the second (p = 0.039) and third cycle of NACT (p = 0.031). Multivariate-adjusted models showed an association between HE4 levels and TR, from the second treatment cycle (p = 0.042) to the third cycle (p = 0.033). Changes from baseline HE4 levels during the first cycle was negative associated with TR. No associations were found between CA125 and TR. Conclusions Serum HE4 levels were independently associated with TR among patients with AOEC treated with NACT, also a reduction between baseline HE4 and first chemotherapy levels was also independently associated with the TR. These findings might be relevant for predicting a lack of response to treatment

Compilación de Proyectos de Investigacion de 1984-2002

Instituto Politecnico Nacional. UPIICS